Literature DB >> 30266158

Hepatitis B and C.

Krupa R Mysore1, Daniel H Leung2.   

Abstract

Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections represent a major global public health and economic burden, with an estimated 257 million and 71 million people, respectively, having chronic infection worldwide. The natural history of HBV and HCV in children depends on age at time of infection, mode of acquisition, ethnicity, and genotype. Most children infected perinatally or vertically remain asymptomatic but are at uniquely higher risk of developing chronic viral hepatitis, progressing to liver cirrhosis and hepatocellular carcinoma (HCC), hence classifying HBV and HCV as oncoviruses. This article discusses the epidemiology, virology, immunobiology, prevention, clinical manifestations, evaluation, and the advances in treatment of hepatitis B and C in children.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Children; Hepatitis; Monitoring; Treatment; Viral

Mesh:

Substances:

Year:  2018        PMID: 30266158     DOI: 10.1016/j.cld.2018.06.002

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  13 in total

Review 1.  Therapeutic Advances in Viral Hepatitis A-E.

Authors:  Navroop Nagra; Richard A Kozarek; Blaire E Burman
Journal:  Adv Ther       Date:  2022-02-27       Impact factor: 3.845

2.  Clinical Efficacy of PEG-IFNα-2a and PEG-IFNα-2b in the Treatment of Hepatitis B e Antigen-Positive Hepatitis B and Their Value in Improving Inflammatory Factors and Hemodynamics in Patients: A Comparative Study.

Authors:  Nina Jia; Wei Gao; Xiaohong Fan; Hong Gao; Xueqing Li; Biantao Mi; Jie Yang
Journal:  Oxid Med Cell Longev       Date:  2022-06-11       Impact factor: 7.310

3.  Chelidonine enhances the antitumor effect of lenvatinib on hepatocellular carcinoma cells.

Authors:  Fang-Jie Hou; Li-Xiao Guo; Kai-Yan Zheng; Jun-Na Song; Qian Wang; Yu-Guang Zheng
Journal:  Onco Targets Ther       Date:  2019-08-19       Impact factor: 4.147

4.  Prevalence of hepatitis B e antigenemia in Bahraini hepatitis B patients: A retrospective, single-center study.

Authors:  Maheeba Abdulla; Mohamed Ghuloom; Hafsa Nass; Nafeesa Mohammed; Eman Farid; Jehad ALQamish
Journal:  JGH Open       Date:  2021-02-08

5.  Hepatitis B virus P protein initiates glycolytic bypass in HBV-related hepatocellular carcinoma via a FOXO3/miRNA-30b-5p/MINPP1 axis.

Authors:  Wenbiao Chen; Jingjing Jiang; Lan Gong; Zheyue Shu; Dairong Xiang; Xujun Zhang; Kefan Bi; Hongyan Diao
Journal:  J Exp Clin Cancer Res       Date:  2021-01-04

Review 6.  The Translational Bridge between Inflammation and Hepatocarcinogenesis.

Authors:  Sabine Gufler; Rita Seeboeck; Christoph Schatz; Johannes Haybaeck
Journal:  Cells       Date:  2022-02-03       Impact factor: 6.600

7.  SIX1/EYA1 are novel liver damage biomarkers in chronic hepatitis B and other liver diseases.

Authors:  Baoyan Xu; Qiao Yang; Yingzi Tang; Zhaoxia Tan; Haiyan Fu; Jing Peng; Xiaomei Xiang; Linlin Gan; Guohong Deng; Qing Mao; Pin-Xian Xu; Yi Jiang; Jianqiang Ding
Journal:  Ann Transl Med       Date:  2021-06

Review 8.  Molecular Mechanisms during Hepatitis B Infection and the Effects of the Virus Variability.

Authors:  Marina Campos-Valdez; Hugo C Monroy-Ramírez; Juan Armendáriz-Borunda; Laura V Sánchez-Orozco
Journal:  Viruses       Date:  2021-06-18       Impact factor: 5.048

9.  Towards the Development of a 3-D Biochip for the Detection of Hepatitis C Virus.

Authors:  Mariia Antipchik; Dmitry Polyakov; Ekaterina Sinitsyna; Apollinariia Dzhuzha; Mikhail Shavlovsky; Evgenia Korzhikova-Vlakh; Tatiana Tennikova
Journal:  Sensors (Basel)       Date:  2020-05-10       Impact factor: 3.576

10.  Identification of hepatitis B virus and liver cancer bridge molecules based on functional module network.

Authors:  Xiao-Bing Huang; Yong-Gang He; Lu Zheng; Huan Feng; Yu-Ming Li; Hong-Yan Li; Feng-Xia Yang; Jing Li
Journal:  World J Gastroenterol       Date:  2019-09-07       Impact factor: 5.374

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.